ArticleStrahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]2026
Clinical target volume radiomics from planning CT for pretreatment response prediction in rectal cancer undergoing chemoradiotherapy.
Article in Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeResponse to neoadjuvant chemoradiotherapy (nCRT) in rectal cancer remains heterogeneous. This exploratory study evaluated whether radiomics features extracted from the clinical target volume (CTV) on pretreatment non-contrast radiotherapy planning CT could provide additional information for pretreatment prediction of poor treatment response.
methodsThis retrospective single-center study included 60 patients with rectal cancer treated with nCRT between 2008 and 2024, including 50 good responders and 10 poor responders. A total of 1148 radiomics features were extracted from the original pretreatment treatment-planning CTV and combined with clinical variables, including age, sex, cT stage, cN stage, log-transformed carcinoembryonic antigen, and tumor-to-anal verge distance. Models were internally evaluated using repeated nested cross-validation with fold-wise ComBat harmonization. Performance was assessed from pooled repeated out-of-fold predictions, including discrimination, apparent calibration, exploratory threshold-based operating characteristics, and decision curve analysis.
resultsThe best-performing combined clinical-radiomics model was Extra Trees, with an area under the receiver operating characteristic curve of 0.754 (95% confidence interval [CI], 0.713-0.789), compared with 0.507 for the clinical-only model. At a post hoc sensitivity-prioritized operating threshold, the combined Extra Trees model achieved sensitivity of 0.94 (95% CI, 0.89-0.98), specificity of 0.47 (95% CI, 0.42-0.51), and negative predictive value of 0.98 in pooled repeated out-of-fold analysis. Decision curve analysis suggested potential net benefit across low-to-moderate threshold probabilities in internal analysis.
conclusionClinical target volume-based radiomics from routine pretreatment non-contrast planning CT may provide exploratory information for prediction of poor response to nCRT in rectal cancer. Because treatment-planning CTVs are routinely generated before radiotherapy, this workflow may be practical for radiotherapy-based research. The findings are hypothesis generating and require external validation before clinical use.
Indexed as
Identifiers
42467205What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.